China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.

Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project ...

On March 19, 2025, China’s National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data (the “Draft Measures”), along with its accompanying ...

TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, ...

In 2025, Yangtze River Pharmaceutical Group (YRPG) made significant progress in both global growth and quality initiatives.

Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore up their pipelines in anticipation of an approaching patent ...

ZHUHAI, GUANGDONG, CHINA, February 5, 2026 /EINPresswire.com/ — As global pharmaceutical manufacturers face increasingly strict environmental regulations, APEX ...

TAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, ...

HONG KONG SAR - Media OutReach Newswire - 10 April 2026 - AilsynBio, an AI-driven drug discovery company, held an ...

Add Yahoo as a preferred source to see more of our stories on Google. Some in the pharmaceutical industry fear tariffs on China could exacerbate U.S. drug shortages. (Spencer Platt—Getty Images) The U ...

America’s medicine cabinet is too important to leave to the mercy of subsidized foreign suppliers and fragile supply chains. Lobbyists in Washington are at it again. They’re warning of calamity if the ...